Testing a maintenance drug to prevent T-cell lymphoma from returning

Plain-English translation of NCT07300514 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated August 2026 · How we translate trials

What is this trial?

This trial is testing a medication called to see if it can help prevent peripheral T-cell lymphoma from returning after you've already had chemotherapy and your cancer has improved. Half of the participants will receive the actual medication, and half will receive a placebo (a dummy pill that looks identical). The goal is to find out whether this treatment helps keep the cancer under control for longer.

Peripheral T-cell lymphoma often comes back even after successful chemotherapy, and there's currently no proven standard treatment to prevent this relapse in patients who can't have a stem cell transplant. This medication has shown promise in earlier studies, so researchers want to test whether it can actually help prevent the cancer from returning.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with one of four specific types of peripheral T-cell lymphoma
your cancer improved (either completely or partially) after your first round of standard chemotherapy
you are either over 65 years old, or under 65 but have chosen not to have a stem cell transplant
your blood counts and organ function are healthy enough to safely take the medication
you completed your chemotherapy within the last 3 months

You likely don't qualify if…

you have stage I disease (the earliest stage of lymphoma)
you have received any JAK or STAT3 inhibitor medications before
you are currently taking certain blood thinner medications that cannot be stopped
you had major surgery or chemotherapy within the last few weeks
you have received certain other cancer treatments (like checkpoint inhibitors or antibody therapies) recently

What participation looks like

You will take either the medication or placebo by mouth every other day for up to 2 years, in cycles of 28 days each. During this time, you'll have regular imaging scans and blood tests to check how your cancer is responding. If your cancer shows a complete response and your blood tests show no remaining cancer cells at the 12-month mark, you may be able to stop treatment early. After treatment ends, you'll continue to be followed for about another year to monitor for any signs of the cancer returning.

Testing a maintenance drug to prevent T-cell lymphoma from returning

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)